Literature DB >> 9637160

Both T-helper-1- and T-helper-2-type lymphokines are depressed in posttrauma anergy.

J C Puyana1, J D Pellegrini, A K De, K Kodys, W E Silva, C L Miller.   

Abstract

BACKGROUND: We have previously shown that an intrinsic postinjury T-cell dysfunction defined as lack of proliferative response to direct stimulation through the T-cell receptor, referred to here as "anergy," occurs in a subgroup of patients with severe trauma and is associated with organ failure. It has been suggested recently that a dominance of T-helper-2 (Th2) lymphokine production might be responsible for immunosuppression and associated with poor patient outcome. Here, we hypothesize that anergy is associated with global failure of T lymphokine (T LK) production, suggesting that poor outcome is not the result of an excess of immunosuppressive T LK (i.e., interleukin (IL)-10) but rather results from lost T-cell regulatory networking.
METHODS: Purified T cells from 37 severely injured trauma patients were cultured and stimulated with alphaCD3/alphaCD4, and proliferation was assessed at 72 hours. Anergy is defined as occurring when the patient's T-cell proliferation to alphaCD3/alphaCD4 is less than 50% of the simultaneously run normal proliferation. Culture supernatants were assessed for T LK production by enzyme-linked immunosorbent assay. Clinical severity was measured by the multiple organ dysfunction syndrome (MODS) and Acute Physiology and Chronic Health Evaluation III scores.
RESULTS: Anergy occurred in 20 of 37 patients, and it usually appeared at greater than 5 to 7 days after injury. There was a global reduction of T LK production during T-cell anergy (IL-2, 2.5%; interferon (IFN)gamma, 30.5%; IL-4, 11.8%; and IL-10, 16.9%) compared with increased or unchanged T LK production during the nonanergic state (IL-2, 83%; IFNgamma, 230%; IL-4, 110%; and IL-10, 307.9%; p < 0.01). There was a significant direct correlation between depressed IL-4 and depressed IFNgamma (r = 0.620, p < 0.001), indicating a diminished LK production of both types of T-helper cells (Th1 and Th2). Decreased IL-2 and IL-10 levels were also specifically correlated to each other during the anergic state (r = 0.91, p < 0.001). The average MODS score for patients during anergy was significantly higher (7.6) than their MODS score in the absence of anergy (4.0, p = 0.01). When IL-2 and IL-10 were measured simultaneously, a predominance of Th2 LK (IL-10) production would result in an IL-10/IL-2 ratio greater than 1. We found, however, that this ratio was not greater than 1 in 80% of assays in which T cells were anergic (p = 0.01).
CONCLUSION: During T-cell anergy there is not a predominance of Th2 lymphokine production but rather a global depression of the T-cell lymphokine profile. Both depressed T-cell proliferation and depressed LK production correlate to poor clinical outcome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9637160     DOI: 10.1097/00005373-199806000-00017

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  12 in total

1.  Distinct roles of trauma and transfusion in induction of immune modulation after injury.

Authors:  Rachael P Jackman; Garth H Utter; Marcus O Muench; John W Heitman; Matthew M Munz; Robert W Jackman; Hope H Biswas; Ryan M Rivers; Leslie H Tobler; Michael P Busch; Philip J Norris
Journal:  Transfusion       Date:  2012-03-27       Impact factor: 3.157

Review 2.  Trauma equals danger--damage control by the immune system.

Authors:  Veit M Stoecklein; Akinori Osuka; James A Lederer
Journal:  J Leukoc Biol       Date:  2012-05-31       Impact factor: 4.962

3.  Gender-based differences in cytokine production after burn injury: a role of interleukin-6.

Authors:  Timothy P Plackett; Richard L Gamelli; Elizabeth J Kovacs
Journal:  J Am Coll Surg       Date:  2009-10-27       Impact factor: 6.113

4.  Primary immune response to keyhole limpet haemocyanin following trauma in relation to low plasma glutamine.

Authors:  P G Boelens; J C M Fonk; A P J Houdijk; R J Scheper; H J T H M Haarman; S Meijer; P A M Van Leeuwen; B M E von Blomberg-van der Flier
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

Review 5.  The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients.

Authors:  Nicholas S Ward; Brian Casserly; Alfred Ayala
Journal:  Clin Chest Med       Date:  2008-12       Impact factor: 2.878

6.  Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis.

Authors:  Richard S Hotchkiss; Katherine C Chang; Mitchell H Grayson; Kevin W Tinsley; Benjamin S Dunne; Christopher G Davis; Dale F Osborne; Irene E Karl
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-07       Impact factor: 11.205

Review 7.  Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony.

Authors:  Guillaume Monneret; Fabienne Venet; Alexandre Pachot; Alain Lepape
Journal:  Mol Med       Date:  2008 Jan-Feb       Impact factor: 6.354

8.  Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic shock patients.

Authors:  Fabienne Venet; Chun-Shiang Chung; Hakim Kherouf; Anne Geeraert; Chistophe Malcus; Françoise Poitevin; Julien Bohé; Alain Lepape; Alfred Ayala; Guillaume Monneret
Journal:  Intensive Care Med       Date:  2008-10-23       Impact factor: 17.440

9.  Failure to normalize lymphopenia following trauma is associated with increased mortality, independent of the leukocytosis pattern.

Authors:  Daithi S Heffernan; Sean F Monaghan; Rajan K Thakkar; Jason T Machan; William G Cioffi; Alfred Ayala
Journal:  Crit Care       Date:  2012-01-20       Impact factor: 9.097

10.  Anti-HMGB1 monoclonal antibody ameliorates immunosuppression after peripheral tissue trauma: attenuated T-lymphocyte response and increased splenic CD11b (+) Gr-1 (+) myeloid-derived suppressor cells require HMGB1.

Authors:  Xiangcai Ruan; Sophie S Darwiche; Changchun Cai; Melanie J Scott; Hans-Christoph Pape; Timothy R Billiar
Journal:  Mediators Inflamm       Date:  2015-01-29       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.